Mucosal vaccines, which use the body's mucosal immune system to fight cancerous cells, represent a promising new avenue in cancer immunotherapy. This paper provides a thorough overview of the role of mucosal vaccines in cancer treatment, emphasizing their benefits, drawbacks, current research, and prospects for the future. There are many different kinds of vaccines for the mucosa, such as live attenuated, inactivated, subunit, DNA, and vector-based vaccines. They function by triggering a systemic immune response against particular cancer antigens by stimulating mucosal immunity at sites such as the respiratory, gastrointestinal, and genitourinary tracts. Enhanced mucosal immune response, needle-free administration, cost-effectiveness, and broad coverage against various cancer types are just a few benefits of this special mechanism. Mucosal vaccines have limitations despite their potential, including the requirement for adjuvants, immune responses specific to a given route, stability issues, and safety concerns. Promising outcomes are being shown by ongoing studies and clinical trials, some of which have assessed safety and efficacy in clinical settings and demonstrated efficacy in preclinical models. In cancer immunotherapy, mucosal vaccines have a wide range of uses, such as treating metastatic disease, preventing cancer from returning, and boosting the effectiveness of immunotherapeutic combinations. Moreover, customized treatment plans based on unique patient profiles may be possible by developing personalized vaccines. Mucosal vaccinations in cancer immunotherapy have a promising future. There is hope for better patient outcomes and worldwide cancer prevention strategies thanks to developments in vaccine technology, integration into standard treatment protocols, and personalized approaches. Finally, mucosal vaccines offer a novel strategy for cancer immunotherapy that has the power to alter patient survival rates and treatment paradigms drastically. Realizing the full potential of mucosal vaccines in the fight against cancer requires ongoing research and clinical development.
Keywords: Adoptive cell therapy, Cancer, Cancer antigens, Immunotherapy, Immunity, Mucosal vaccine, Mucosal-associated lymphoid tissues, Systemic immune response.
